Lincomycin
Based on 5 publication(s) in Google Scholar
Lincomycin (U-10149) is an orally active lincosamide antibiotic. Lincomycin binds to the ribosomes of Gram-positive bacteria to inhibit protein synthesis. Lincomycin can inhibit chloroplast translation, disrupt chloroplast integrity, and activate chloroplast-to-nucleus retrograde signaling in Arabidopsis thaliana seedlings. Lincomycin induces alterations in lipid profiles and liver injury, disrupts blood glucose and insulin levels, and increases growth rate in mice.
For research use only. We do not sell to patients.
- Purity: 99.82%
- CAS No.: 154-21-2
- Formula: C18H34N2O6S
- Molecular Weight:406.54
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Antibacterial Compound Library
HY-L049
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Alkaloids Library
HY-L071
-
Microbial Metabolite Library
HY-L084
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Animal Drug Library
HY-L218
-
Natural Product Diversity Scaffold Library
HY-L245
-
Bacteria-Sourced Compound Library
HY-L254
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Lincomycin
MoreAll Antibiotic Isoforms
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
Lincomycin (0.5-10 μg/mL; 10 days) can enhance the biosynthesis of actinorhodin and undecylprodigiosin in liquid-cultured Streptomyces coelicolor A3(2) 1147[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR (6-week-old male)[3]
-
Dosage:33 mg/kg
-
Administration:p.o.; ad libitum daily; 8 weeks
-
Result:Resulted in a significant
increase in growth rate of mice (50.11 %) over an 8 weeks period.
Caused suppression in inflammatory response.
Exhibited altered lipid profiles and liver damage suggestive of early-stage non-alcoholic fatty liver disease (NAFLD).
Chemical Information
-
CAS No. 154-21-2
-
Appearance Solid
-
Molecular Weight 406.54
-
Formula C18H34N2O6S
-
Color White to off-white
-
SMILES
O=C([C@@H]1C[C@H](CN1C)CCC)N[C@@H]([C@@]2([H])O[C@@H]([C@@H]([C@H]([C@H]2O)O)O)SC)[C@H](O)C
-
Synonyms
U-10149
-
Structure Classification
-
Initial Source
Streptomyces lincolnensis var. lincolnensis
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Targeting Peptostreptococcus anaerobius with an Iron-Based Nanozyme Reverses Ferroptosis Resistance and Enhances Antitumor Immunity in Colorectal Cancer. [Abstract]2026 Jan 12:e16272. PMID: 41524179 -
Chemosphere
Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]2019 Jun:225:378-387. PMID: 30884299 -
-
Microb Biotechnol
Attenuator LRR - a regulatory tool for modulating gene expression in Gram-positive bacteria. [Abstract]2021 Nov;14(6):2538-2551. PMID: 33720523 -
Microbiol Spectr
2025 Aug 29:e0059025. PMID: 40879403
Solvent & Solubility
DMSO : 100 mg/mL (245.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Veciana N, et al. BBX16 mediates the repression of seedling photomorphogenesis downstream of the GUN1/GLK1 module during retrograde signalling. New Phytol. 2022;234(1):93-106. [Content Brief]
[2]. Imai Y, et al. Lincomycin at Subinhibitory Concentrations Potentiates Secondary Metabolite Production by Streptomyces spp. Appl Environ Microbiol. 2015;81(11):3869-3879. [Content Brief]
[3]. Ni H, et al. Lincomycin as a growth-promoting antibiotic induces metabolic and immune dysregulation in animals. Sci Total Environ. 2024;957:177780. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4598 mL | 12.2989 mL | 24.5978 mL | 61.4946 mL |
| 5 mM | 0.4920 mL | 2.4598 mL | 4.9196 mL | 12.2989 mL | |
| 10 mM | 0.2460 mL | 1.2299 mL | 2.4598 mL | 6.1495 mL | |
| 15 mM | 0.1640 mL | 0.8199 mL | 1.6399 mL | 4.0996 mL | |
| 20 mM | 0.1230 mL | 0.6149 mL | 1.2299 mL | 3.0747 mL | |
| 25 mM | 0.0984 mL | 0.4920 mL | 0.9839 mL | 2.4598 mL | |
| 30 mM | 0.0820 mL | 0.4100 mL | 0.8199 mL | 2.0498 mL | |
| 40 mM | 0.0615 mL | 0.3075 mL | 0.6149 mL | 1.5374 mL | |
| 50 mM | 0.0492 mL | 0.2460 mL | 0.4920 mL | 1.2299 mL | |
| 60 mM | 0.0410 mL | 0.2050 mL | 0.4100 mL | 1.0249 mL | |
| 80 mM | 0.0307 mL | 0.1537 mL | 0.3075 mL | 0.7687 mL | |
| 100 mM | 0.0246 mL | 0.1230 mL | 0.2460 mL | 0.6149 mL |
Lincomycin Related Classifications
HY-117660 Related Classifications
Powered by Bioz
- Lincomycin
- 154-21-2
- U-10149
- U10149
- U 10149
- Antibiotic
- Bacterial
- DNA/RNA Synthesis
- non-alcoholic fatty liver disease
- gut microbiota
- Arabidopsis seedlings
- chloroplast-to-nucleus retrograde signalling
- Streptomyces strains
- type 2 diabetes mellitus
- plastid translation
- BBX16
- ribosome inhibitor
- Gram-positive bacterial ribosomes
- Inhibitor
- inhibitor
- inhibit